![]() With commercial insurers and CMS demanding evidence in support of coverage decisions, your choice in bone grafting material could impact your bottom line. Efficacy of i-Factor Bone Graft versus Autograft in Anterior. Novel i-FACTOR Biologic Bone Graft Shown to improve clinical outcomes in ALIF procedures Cerapedics, a privately-held orthobiologics company, today announced that results from the first prospective clinical study evaluating the safety and efficacy of i-FACTOR bone graft in anterior lumbar interbody fusion (ALIF) have been published in the peer-reviewed Journal of Neurosurgery: Spine. Despite a market that boasts over 300 options, only two have satisfied the highest regulatory requirements for use in spinal fusion and had their Level I data go into publication. According to the manufacturer, Osteocel Plus mimics the biologic properties of autograft. An advanced biologics company with i-FACTOR Peptide Enhanced Bone Graft powered by P-15 Osteogenic Cell Binding Peptide Cerapedics is an advanced. Mind the Gap! Closing the Fusion Divide With Evidence-Based Orthobiologics Thursday, April 20th, 2017 | 11:00am - 12:00pm CTĪt a time when therapeutic decisions are based on reasoned burdens of proof, there is strikingly little evidence supporting the use of most bone graft products. Efficacy of i-factor bone graft versus autograft in anterior cervical discectomy and fusion: results of the prospective, randomized, single-blinded food and. ![]() Becker's Infection Control & Clinical Quality E-Weekly.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |